Stock Report: AstraZeneca PLC ADS (AZN) Report Updated: May 20, 2013 | Print This Page

AstraZeneca PLC engages in the discovery, development, and commercialization of prescription medicines for gastrointestinal, cardiovascular, neuroscience, respiratory and inflammation, oncology, and infectious diseases worldwide. Its principal products include Atacand for hypertension and heart failure; Crestor for managing cholesterol levels; Nexium for acid reflux; Losec/Prilosec for the treatment of acid related diseases; Seloken/Toprol-XL for hypertension, heart failure, and angina; Seroquel IR for schizophrenia and bipolar disorders; and Seroquel XR for schizophrenia, bipolar disorder, and major depressive disorders. The company principal products also comprise Symbicort for asthma and chronic obstructive pulmonary diseases; Synagis for RSV, a respiratory infection in infants; and Zoladex for prostate and breast cancer. In addition, it has 86 pipeline projects, which include 79 projects in various clinical phases of development and 7 approved or launched projects. The company markets its products primarily to primary care and specialist doctors through distributors or local representative offices. AstraZeneca PLC has a strategic partnership with KNODE Inc. for the development of web-based solution; and a strategic alliance with Regulus Therapeutics, LLC to discover, develop, and commercialize microRNA therapeutics. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was founded in 1992 and is headquartered in London, the United Kingdom.